Pierwotne guzy neuroendokrynne piersi, opis czterech przypadków

Steinhof-Radwańska, Katarzyna; Barczyk, Anna; Powązka, Piotr; Kajor, Maciej; Dobrosz, Zuzanna; Świątkowska-Szlachta, Ewa; Pilch-Kowalczyk, Joanna

doi:10.5603/ep.a2017.0049

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This rare malignancy has an incidence of 0.3 to 1% of all breast cancers [16], occurring predominately in postmenopausal women [17]. The histopathological assessment of these tumours is difficult, and in most cases the correct diagnosis is made after proper examination of the postsurgical specimen [18].…”

Section: Case Reportmentioning

confidence: 99%

Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours — single-centre experience of two cases

Salvia

Brizzi

Muratori

et al. 2019

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: Neuroendocrine neoplasms (NENs) are a rare and heterogeneous group of tumours, with a variety of primary origins and variable aggressiveness. NENs with an atypical primary origin, such as breast and retroperitoneal NENs, are extremely rare. As a consequence, an established diagnostic and therapeutic strategy in this particular subgroup is lacking. The combination of capecitabine and temozolomide, called CAPTEM regimen, has produced promising response rates in patients with grade 1 or 2 neuroendocrine tumours of multiple origins. Case presentation: The first is a case of a 68-year-old woman with a metastatic primary breast neuroendocrine tumour, treated with cisplatin plus etoposide as first line, followed by CAV scheme (cyclophosphamide, doxorubicin, and vincristine), and subsequently treated, in third line with the CAPTEM regimen, obtaining radiological response and good tolerance. The second is the case of a 66-year-old woman affected by a metastatic primitive retroperitoneal NET G2. The patient progressed after a somatostatin analogue-based first line, whereas the CAPTEM regimen led to a partial and durable response with a favourable safety profile. Conclusions: CAPTEM chemotherapy has been shown to be an active and safe therapeutic option in advanced, metastatic G1/2 atypical primary NENs.

show abstract

Section: Case Reportmentioning

confidence: 99%